

LILRB2/CD85d/ILT-4 Protein, Human (HEK293, His)

Cat. No.:	HY-P70168
Synonyms:	rHuLeukocyte immunoglobulin-like receptor subfamily B member 2/LILRB2, His; Leukocyte Immunoglobulin-Like Receptor Subfamily B Member 2; LIR-2; Leukocyte Immunoglobulin-Like Receptor 2; CD85 Antigen-Like Family Member D; Immunoglobulin-Like Transcript 4; ILT-4; Monocyte/Macrophage Immunoglobulin-Like Receptor 10; MIR-10; CD85d; L
Species:	Human
Source:	HEK293
Accession:	AAH36827.1 (Q22-H458)
Gene ID:	10288
Molecular Weight:	58-75 kDa

PROPERTIES

AA Sequence	<pre> QTGTIPKPTL WAEPDSVITQ GSPVTLSCQG SLEAQEYRLY REKKASASWIT RIRPELVKNG QFHIPSITWE HTGRYGCQYY SRARWSELSD PLVLVMTGAY PKPTLSAQPS PVVTSGGRVT LQCESQVAFG GFILCKEGED EHPQCLNSQP HARGSSRAIF SVGPVSPNRR WSHRCYGYDL NSPYVWSSPS DLLELLVPGV SKKPSLSVQP GPVVAPGESL TLQCVSDVGY DRFVLYKEGE RDLRQLPGRQ PQAGLSQANF T L G P V S R S Y G G Q Y R C Y G A Y N LSSEWSAPSD PLDILITGQI HGTFFISVQP GPTVASGENV TLLCQSWRQF HTFLLTKAGA ADAPLRLRSI HEYPKYQAEF PMSPV TSAHA GTYRCYGS LN SDPYLLSHPS EPLELVVSGP SMGSSPPPTG PISTPAGPED QPLTPTGSDP QSGLGGRH </pre>
Appearance	Lyophilized powder.
Formulation	Lyophilized from a 0.2 µm filtered solution of 20 mM PB, 150 mM NaCl, pH 7.2.
Endotoxin Level	<1 EU/µg, determined by LAL method.
Reconstitution	It is not recommended to reconstitute to a concentration less than 100 µg/mL in ddH ₂ O. For long term storage it is recommended to add a carrier protein (0.1% BSA, 5% HSA, 10% FBS or 5% Trehalose).
Storage & Stability	Stored at -20°C for 2 years. After reconstitution, it is stable at 4°C for 1 week or -20°C for longer (with carrier protein). It is recommended to freeze aliquots at -20°C or -80°C for extended storage.
Shipping	Room temperature in continental US; may vary elsewhere.

DESCRIPTION

Background

The LILRB2/CD85d/ILT-4 Protein serves as a receptor for class I MHC antigens, demonstrating recognition across a broad spectrum of HLA-A, HLA-B, HLA-C, HLA-G, and HLA-F alleles. It plays a crucial role in immune response down-regulation and the establishment of tolerance. Specifically, it recognizes HLA-G in complex with B2M/beta-2 microglobulin and a nonamer self-peptide, leading to the differentiation of type 1 regulatory T cells and myeloid-derived suppressor cells, crucial for maintaining maternal-fetal tolerance. LILRB2 competes with CD8A for binding to class I MHC antigens and inhibits FCGR1A-mediated cellular responses, including phosphorylation of proteins and mobilization of intracellular calcium ions. Moreover, it interacts with PTPN6 when phosphorylated and binds to FCGR1A. The direct interactions with peptide-bound HLA-G-B2M and HLA-F-B2M further highlight its involvement in immune modulation.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA